EVAPORATE, NCT02926027: Effect of Vascepa on Improving Coronary Atherosclerosis in People With High Triglycerides Taking Statin Therapy |
|
|
| Completed | 4 | 80 | US | Vascepa, icosapent ethyl, placebo | Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center, Intermountain Research and Medical Foundation | Hypertriglyceridemia | 05/20 | 08/20 | | |
| Terminated | 4 | 39600 | US | Icosapent ethyl, Vascepa | Kaiser Permanente, Amarin Corporation | Covid19, Atherosclerosis, Cardiovascular Diseases, Upper Respiratory Tract Infections | 12/22 | 12/22 | | |
ARTCAP, NCT06280976: Aggressive Risk-Prevention Therapies for Coronary Atherosclerotic Plaque (ART-CAP) |
|
|
| Recruiting | 4 | 200 | US | Statin, atorvastatin, Aspirin tablet, aspirin 81 mg, Nexlizet, bempedoic acid-ezetimibe, LEQVIO, inclisiran, Vascepa, icosapent ethyl, Jardiance, empagliflozin, Colchicine | University of Louisville | Coronary Artery Disease, Atherosclerosis, Heart Attack | 01/29 | 01/29 | | |
